Are Patients Receiving Guideline-Concordant Treatment for Lung Cancer?

Among patients screened for a national trial, rates of such treatment were low, thereby calling into question extrapolation of findings from clinical trials.

Adequate surgery and adjuvant cisplatin chemotherapy have been shown to improve overall survival in patients with resectable non–small-cell lung cancer (NSCLC) who are able to undergo surgery. Investigators retrospectively assessed rates of these guideline-recommended treatments in patients screened for ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial), a clinical trial platform of the National Cancer Institute that supports randomized trials of novel adjuvant therapies. The cohort included 2833 patients with stage IB–IIIA NSCLC (tumors ≥4 cm and/or positive lymph nodes) enrolled at academic and community sites across the U.S.

Findings were as follows:

95% underwent anatomic surgical resection
53% had adequ…

Reviewing Author

Jyoti D. Patel, MD, FASCO

Disclosures

Consultant/Advisory BoardTakeda; AstraZeneca; AnHeart; Lilly; AbbVie; Blueprint; Gilead; Sanofi; Daiichi Sankyo; Genentech

Jyoti D. Patel, MD, FASCO

Disclosures

Consultant/Advisory BoardTakeda; AstraZeneca; AnHeart; Lilly; AbbVie; Blueprint; Gilead; Sanofi; Daiichi Sankyo; Genentech

Are Patients Receiving Guideline-Concordant Treatment for Lung Cancer?

Topics

Reviewing Author